NCT01924143View on ClinicalTrials.gov

TD-9855 Mass Balance Study

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

December 31, 2013

Conditions
ADHDFibromyalgia
Interventions
DRUG

TD-9855

radiolabeled (100 µCi \[14C\]-Labeled) TD-9855 (20 mg)

Trial Locations (1)

68502

Lincoln

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT01924143 - TD-9855 Mass Balance Study | Biotech Hunter | Biotech Hunter